Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) reports strong financial and operational results for Q3 2025, showing a 275% increase in shareholder equity, 50% decrease in total liabilities, and US$572,000 in gains from its digital asset portfolio. The company remains in a solid financial position with sufficient capital resources to operate beyond March 2027.

In Q3 2025, Quantum BioPharma saw a 50% reduction in total liabilities and a 275% increase in shareholder equity. The company’s debt-to-equity ratio improved by 87%, and liquidity also improved significantly. General and Administrative expenses decreased by approximately US$210,000 compared to the previous year.

Quantum BioPharma continues to make progress with its multiple sclerosis drug, Lucid-21-302 (“Lucid-MS”). Phase 1 oral toxicity studies show no side effects, and the company has signed an agreement for an IND application package with the FDA. The drug has the potential to revolutionize multiple sclerosis treatment.

Unbuzzd Wellness Inc., the licensee of Quantum’s asset unbuzzd, is seeing market growth and has launched a capital raise of up to $5 million USD. There will be no equity dilution for Quantum shareholders. Unbuzzd is a supplement proven to accelerate alcohol metabolism and reduce hangover symptoms, with increasing sales on Amazon and Unbuzzd’s website.

Health Canada has granted a Product License for Quantum’s natural health product, Qlarity, allowing sales in Canada. The company retains ownership of 19.86% of Unbuzzd Wellness Inc. and receives royalty payments from unbuzzd sales. Quantum is also engaged in a lawsuit against CIBC and RBC regarding alleged stock market manipulation.

Quantum BioPharma is focused on developing innovative treatments for neurodegenerative disorders and alcohol health. The company’s lead compound, Lucid-MS, shows promise in treating multiple sclerosis. Management believes the company is well-positioned for future growth and is committed to maintaining a strong financial position.

Read more at Globe Newswire: Quantum Biopharma Reports Strong Third Quarter Results